PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma By Ogkologos - February 9, 2026 29 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PACT-21 CASSANDRA study Source RELATED ARTICLESMORE FROM AUTHOR Antitumour Activity of Rezatapopt Provides Proof of Concept for p53 Reactivation in Patients with TP53 Y220C-mutated Solid Tumours Rare Disease Day 2026: Advancing equity for people living with rare cancers in Europe EMA Recommends Extension of Therapeutic Indications for Ponatinib MOST POPULAR What Do “Health Equity” and “Quality Care” Mean in Cancer Care? December 20, 2022 如何捐赠头发来帮助癌症患者 April 13, 2022 Single-Fraction SABR Preferred from Resource and Patient Perspectives for Pulmonary Oligometastases September 14, 2021 Longitudinal Molecular Profiling of CTCs Captures New Insights in mRCC June 1, 2022 Load more HOT NEWS Stress-Induced Immune Changes May Help Cancer Spread Truck Driver Saves People From Bus Fire On Christmas Eve Temporary Interruption of Adjuvant Endocrine Treatment to Attempt Pregnancy Does Not... FDA Approves Pembrolizumab with Enfortumab Vedotin-ejfv for Muscle Invasive Bladder Cancer
